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Abstract (297 words) 84 
Objective 85 
In order to test the hypothesis that dimethyl fumarate (DMF, Tecfidera®) elicits 86 
different biological changes from DMF combined with monoethyl fumarate (MEF) 87 
(Fumaderm®, a psoriasis therapy), we investigated DMF and MEF in rodents and 88 
cynomolgus monkeys. Possible translatability of findings was explored with 89 
lymphocyte counts from a retrospective cohort of MS patients.   90 
 91 
Methods 92 
In rodents, we evaluated pharmacokinetic and pharmacodynamic effects induced 93 
by DMF and MEF monotherapies or in combination (DMF/MEF). Clinical 94 
implications were investigated in a retrospective, observational analysis of MS 95 
patients treated with DMF/MEF (n = 36).  96 
 97 
Results 98 
In rodents and cynomolgus monkeys, monomethyl fumarate (MMF, the primary 99 
metabolite of DMF) exhibited a higher brain penetration, whereas MEF was 100 
preferentially partitioned into the kidney. In mice, transcriptional profiling for DMF 101 
and MEF alone identified both common and distinct pharmacodynamic 102 
responses, with almost no overlap between DMF- and MEF-induced differentially 103 
expressed gene profiles in immune tissues. The nuclear factor (erythroid-derived 104 
2)-like 2 (Nrf2)-mediated oxidative stress response pathway was exclusively 105 





treatment demonstrated that DMF and MEF functionally interact to modify DMF- 107 
and MEF-specific responses in unpredictable ways. In MS patients, DMF/MEF 108 
treatment led to early and pronounced lymphocyte suppression, predominantly 109 
CD8+ T cells.  110 
In a multivariate regression analysis, absolute lymphocyte count (ALC) was 111 
associated with age at therapy start, baseline ALC, and DMF/MEF dosage, but 112 
not with previous immunosuppressive medication and gender.  113 
Further, ALC increased in a small cohort of MS patients (n = 6/7) after switching 114 
from DMF/MEF to DMF monotherapy.  115 
 116 
Conclusions 117 
Fumaric acid esters (FAEs) exhibit different biodistribution and may elicit different 118 
biological responses; furthermore, pharmacodynamic effects of combinations 119 
differ unpredictably from monotherapy. Strong potential to induce lymphopenia in 120 
MS patients may be a result of activation of apoptosis pathways by MEF 121 
compared with DMF. 122 
 123 
Glossary 124 
ALC = absolute lymphocyte count; DEG = differentially expressed gene; DMF = 125 
dimethyl fumarate; FAE = fumaric acid esters; GAPDH = glyceraldehyde 3-126 
phosphate dehydrogenase; GCRMA = GC-content-based Robust Multi-Array 127 
Average; GSH = glutathione; IACUC = Institutional Animal Care and Use 128 





interquartile range; Keap1 = Kelch-like ECH-associated protein 1; LI = 130 
lymphopenia index; MEF = monoethyl fumarate; MLN = mesenteric lymph node; 131 
MMF = monomethyl fumarate; MS = multiple sclerosis; Nrf2 = nuclear factor 132 
(erythroid-derived 2)-like 2; QC = quality control; RQS = RNA Quality Score; 133 





Introduction (≤250, currently 235) 135 
Multiple sclerosis (MS) is a chronic inflammatory, demyelinating, autoimmune 136 
disease of the CNS.1 During different MS disease stages, oxidative stress 137 
precipitated by mitochondrial damage also may contribute to oligodendrocyte and 138 
neuronal injury.2 Fumaric acid esters (FAE) exhibit pleiotropic immunomodulatory 139 
effects, as well as antioxidative properties. The FAE, dimethyl fumarate (DMF), 140 
which has monomethyl fumarate (MMF) as its primary metabolite, is an oral 141 
treatment approved for use in patients with relapsing-remitting MS (RRMS),3, 4 142 
clinically isolated syndrome, and active secondary progressive MS.3 Efficacy of 143 
DMF and a combination of different salts of monoethyl fumarate (MEF) was 144 
investigated in an early exploratory study in patients with RRMS5 and is marketed 145 
in Germany as an oral therapeutic to treat psoriasis (DMF/MEF, Fumaderm®). 146 
It is unclear whether different FAEs are functionally equivalent and if a 147 
combination treatment could alter pharmacological properties and clinical 148 
parameters, although in vitro evidence shows that different FAEs may stimulate 149 
distinct responses.6-8 Both DMF and MEF treatment are associated with 150 
lymphopenia in some patients; however, the underlying mechanisms and relative 151 
contributions of each FAE are unknown.9, 10  152 
We hypothesized that the standard clinical regimen of DMF and DMF/MEF 153 
might have different pharmacokinetic distributions and provoke different 154 
pharmacodynamic responses. We administered FAEs (DMF, MEF, DMF/MEF) 155 





distribution in various tissues and changes in transcriptional profiles. Finally, we 157 
evaluated lymphopenia in patients with MS treated with DMF/MEF.  158 
 159 
Materials and methods 160 
Animals 161 
All procedures involving animals were performed in accordance with standards 162 
established in the Guide for the Care and Use of Laboratory Animals (US 163 
National Institutes of Health). All rodent animal protocols were approved by the 164 
Biogen Institutional Animal Care and Use Committee (IACUC). Animals used 165 
included female C57BL/6 mice aged 8–10 weeks (Jackson Laboratories, Bar 166 
Harbor, ME), male Sprague Dawley rats aged 12–14 weeks (Harlan 167 
Laboratories, Indianapolis, IN or Charles River Laboratories, Wilmington, MA), or 168 
female cynomolgus monkeys weighing 2–4 kg (dosing excretion studies were 169 
conducted at Charles River Laboratories [Reno, NV] using protocols approved by 170 
their IACUC).  171 
 172 
Compound dosing 173 
For transcriptional profiling and biodistribution studies, C57BL/6 mice or Sprague 174 
Dawley rats were dosed with DMF, a mixture of MEF salts (Ca2+, Mg2+, and Zn2+ 175 
in the ratio 91.5%:5.2%:3.2%), or a combination of DMF and MEF salts to mimic 176 
the ratio of fumarates in Fumaderm®. DMF, MEF, and DMF/MEF were 177 
formulated as fine suspensions in 0.8% hydroxypropyl methylcellulose (vehicle) 178 





(the efficacious dose in a mouse experimental autoimmune encephalomyelitis 180 
model); MEF was dosed at 79.2 mg/kg (total MEF salts) representing the 181 
proportional MEF dose in Fumaderm®; and DMF/MEF, which is reflective of the 182 
ratio of DMF:MEF salts in Fumaderm® used in the clinic, was comprised of DMF 183 
100 mg/kg and MEF 79.2 mg/kg. Mice received either a single dose (10 mL/kg 184 
for PK) or 10 daily doses (10 mL/kg) of FAEs or vehicle-only control (0.8% 185 
hydroxypropyl methylcellulose) via oral gavage. For urine excretion studies, rats 186 
were dosed (30 mg/kg) with a mixture of DMF (55.5 %), Ca2+ MEF (39.8 %), 187 
Mg2+ MEF (2.4%), Zn2+ MEF (1.49%), and fumaric acid (0.98%), reflective of 188 
Fumaderm® dosing. Cynomolgus monkeys were dosed (50 mg/kg) with either 189 
DMF or a mixture of MEF salts in the same proportions used in rats and mice. 190 
 191 
In vivo gene expression profiling 192 
Whole blood and, after perfusion, tissues were collected from naive C57Bl/6 mice 193 
dosed with vehicle, DMF, a mixture of MEF salts, or DMF/MEF at 12 hours after 194 
the final oral dose (10-day series), and snap frozen. RNA was prepared from 195 
tissues and whole blood per standard practice. RNA integrity was assessed 196 
using the HT RNA reagent kit (part number 760410, Caliper Life Sciences, 197 
Hopkinton, MA) using a LabChip GX (PerkinElmer, Waltham, MA). RNA samples 198 
with an RNA Quality Score (RQS) >8.0 were considered high quality for 199 
microarray profiling. Sample labeling, hybridization, and scanning were 200 
performed as described11 using an Affymetrix chip HT-MG-430 PM (Affymetrix, 201 





measures.12 All sample scans that passed QC were included in the analysis; 203 
these 204 CEL files (GEO accession number GSE63343) were either pooled all 204 
together or segregated based on tissue and subjected to content-based GC-205 
Robust Multi-Array Average (GCRMA) normalization (version 2.20.0).13, 14  206 
To identify genes that change uniquely in response to DMF or MEF 207 
administration in each individual tissue, a linear modeling approach was used to 208 
fit gene expression levels (log2 transformed) according to defined groups of 209 
samples and Bayesian posterior error analysis as implemented by Smyth 210 
(Bioconductor library limma, version 3.4.5).15 Genes were considered 211 
significantly different in DMF-vs-vehicle and MEF-vs-vehicle if they met the 212 
following criteria: (1) average normalized signal intensity >4; (2) logarithm (base 213 
10) of odds (“lods”) score >0; and (3) fold change >1.5. All calculations and 214 
analyses were carried out using R (version 2.11.1) and Bioconductor.16  215 
Alternately, samples across all tissues and blood were pooled and 216 
normalized together to avoid characterizing tissue-to-tissue variability in the 217 
limited subset of tissues sampled, and to fully capture all differences in 218 
DMF/MEF responses; this approach generalized the analysis and allowed us to 219 
find those probe sets that were specifically changing due to DMF or MEF, as well 220 
as those probe sets that exhibited a DMF:MEF interaction effect. The following 221 
linear mixed model was applied to the normalized data set: 222 
Gene Expression ~ DMF + MEF + DMF:MEF + random(tissue)  223 
Interaction probe sets were defined as those with a Bonferroni-adjusted p value 224 





interaction term) was fit to probe sets that exhibited no interaction effect. 226 
Similarly, probe sets were considered significant and specific to DMF if the 227 
Bonferroni-corrected p value was <0.05 for the DMF term and >0.05 for the MEF 228 
term (and no interaction effect was found). MEF-specific probe sets were 229 
identified by requiring the Bonferroni-corrected p value to be >0.05 for DMF and 230 
<0.05 for MEF. 231 
An in vivo MEF-DMF interaction was evaluated by analyzing the specific 232 
differentially expressed genes (DEGs) modulated when these 2 compounds were 233 
co-administered (DMF 100 mg/kg and MEF salts 79.2 mg/kg). The absolute 234 
value of the difference between (DMF – vehicle) and (combination – vehicle) was 235 
calculated for each of the identified interaction probe sets, and presented as the 236 
log2 absolute difference for each probe set. In order to identify the most highly 237 
enriched molecular pathways, the sets of DMF-specific, MEF-specific, and 238 
DMF/MEF interaction probe sets were analyzed using Ingenuity Pathway 239 
Analysis (IPA) software (Qiagen, Germantown, MD). The top 10 enriched 240 
pathways for each were compared with each other for p value significance.  241 
 242 
Bioanalytical studies 243 
For biodistribution studies, immediately following blood collection, stabilizer 244 
(sodium fluoride solution, 250 mg/mL NaF in water) was added to each blood 245 
sample (10 mg/mL final) in a chilled lithium heparin blood collection tube (to 246 
inhibit metabolism of MMF or MEF), and plasma was separated from whole blood 247 





at -80°C until analyzed. MEF and MMF were measured in all experiments. MMF 249 
represents the main metabolite of DMF, which itself cannot be detected in 250 
systemic circulation after oral administration due to rapid pre-systemic 251 
conversion in vivo. Sample extracts were evaluated by liquid chromatography 252 
tandem mass spectrometry to determine MMF and MEF levels, using absolute 253 
quantitation based on standard curves spiked in the appropriate biomatrix. 254 
Results are expressed as absolute concentration (ng/g of tissue or ng/mL of 255 
plasma) and relative concentration expressed as a percentage of plasma 256 
concentration.  257 
To measure the renal excretion of MMF and MEF, Sprague Dawley rats 258 
received a single oral dose of 30 mg/kg DMF plus MEF salts in the Fumaderm® 259 
ratio (DMF [55.5 %], Ca2+ MEF [39.8 %], Mg2+ MEF [2.4%], Zn2+ MEF [1.49%], 260 
and fumaric acid [0.98%]). In a separate study, cynomolgus monkeys received a 261 
single oral dose of 50 mg/kg DMF or MEF salts. In both studies, urine was 262 
collected over a 24-hour period and analyzed for MMF and MEF levels.  263 
 264 
Patients with MS 265 
Patients were identified by retrospective analysis of medical records from a 266 
single university hospital. Clinical characteristics (table e-1) of the majority of 267 
patients (RRMS or relapsing progressive MS, n = 18; progressive MS, n = 17; 268 
neuromyelitis optica, n = 1) treated with DMF/MEF (Fumaderm®, mean [SD] 285 269 
[123] mg) in this retrospective, observational, cross-sectional study were 270 





absolute lymphocyte count (ALC) of the DMF/MEF cohort were obtained 1 week 272 
(median and interquartile range [IQR]) before initiation of DMF/MEF and every 3 273 
months thereafter. The 7 patients who switched from DMF/MEF to DMF switched 274 
within a mean (SD) of 0.9 (2.3) weeks (6/7 no treatment-free interval, 1 patient 6 275 
weeks interval). In these patients, a lymphopenia index (LI) normalized for 276 
dosage of the DMF component was calculated using the following operator: 277 
(lymphocyte count during medication – baseline lymphocyte count)/mg of DMF. 278 
Statistical analyses including a multivariate regression analysis, Chi-square, and 279 
Spearman rho correlation were performed with SPSS 20 (IBM, Armonk, NY).  280 
 281 
Standard protocol approvals, registrations, and patient consents 282 
The retrospective observation was approved by the local ethics committee (Ruhr 283 
University Bochum; numbers 5408-15 and 4797-13) and conducted in 284 
accordance with the Declaration of Helsinki, the International Conference on 285 
Harmonisation Guideline for Good Clinical Practice, and all applicable laws and 286 
regulations.  287 
 288 
Data availability statement 289 
Data supporting this article can be requested via the corresponding authors.  290 
 291 





Biodistribution of DMF metabolite (MMF) and MEF in mice and rats 293 
Thirty minutes after DMF administration by oral gavage, MMF was broadly 294 
distributed throughout the bodies of both rats and mice. MMF (dosed as DMF) 295 
achieved higher brain penetration after oral administration compared with MEF, 296 
by both absolute and relative concentration (mouse, figure 1, A vs B; rat, figure 1, 297 
C vs D). In contrast, MEF preferentially partitioned to the kidney, leading to 298 
higher absolute and relative concentration. These differences led to an increased 299 
brain to plasma ratio for DMF (p < 0.001) (figure 1E) and conversely higher 300 
kidney to plasma ratio for MEF compared with each other (p < 0.01) (figure 1F). 301 
Differences in biodistribution remained similar after a 10-day dosing period (data 302 
not shown). 303 
 304 
Renal excretion of MMF and MEF is significantly different in rats and 305 
cynomolgus monkeys 306 
Consistent with pharmacokinetic and tissue distribution data, mean excretion of 307 
intact MEF was significantly higher relative to MMF in rats (9-fold; p < 0.05) and 308 
in cynomolgus monkeys (26-fold; p < 0.001) (data not shown). Thus, the kidney 309 
experienced significantly greater exposure to MEF compared with MMF (after 310 
DMF dosing), which might be expected as the kidney to plasma ratio was higher 311 






Interaction between DMF and MEF based on gene expression changes in 314 
mice  315 
As determined by induced gene expression changes relative to vehicle, DMF, 316 
MEF, and their combination exhibited varied pharmacodynamic activity based on 317 
tissue type, with many gene expression changes unique to either DMF or MEF 318 
exposure (figure e-1). All samples were normalized and analyzed together to 319 
identify genes that exhibit a change in expression uniquely due to DMF or MEF, 320 
as well as interaction effects between DMF and MEF. In the combined tissues 321 
data set, 487 genes were found to change specifically from DMF treatment. 322 
These genes were enriched for pathways for the nuclear factor (erythroid-derived 323 
2)-like 2 (Nrf2)-mediated oxidative stress response, glutathione (GSH)-mediated 324 
detoxification, and other environmental sensing pathways (e.g., aryl hydrocarbon 325 
receptor signaling) (Table e-2). In total, 224 genes were identified with 326 
expression changes specifically due to MEF; they were enriched for death 327 
receptor signaling pathway, apoptosis signaling, and autophagy-related pathway. 328 
The absolute mean value of each tissue for the DMF- and MEF-specific groups 329 
was subjected to unsupervised hierarchical clustering (figure 2A). DMF specificity 330 
was more pronounced in the mesenteric lymph node (MLN), inguinal lymph node 331 
(ILN), spleen, and whole blood, whereas MEF specificity was found 332 
predominantly in the kidney and MLN. After combination therapy, 132 DEGs 333 
exhibited a significant interaction effect between DMF and MEF. The most 334 
pronounced interactions between fumarates were found in tissues related to 335 





which is of interest for the relative amount of lymphocyte suppression by each 337 
fumarate compound. The unfolded protein response (a stress response) and 338 
neurodegenerative signaling (e.g., Huntington’s disease, RNA polymerase III 339 
assembly, and protein degradation) pathways were uniquely enriched for DMF 340 
and MEF interaction. These biological trends were constant regardless of 341 
whether the tissues were pooled or kept separate for the analysis.  342 
 343 
DMF/MEF combination induces fast and moderate-to-severe lymphopenia 344 
in patients with MS  345 
To assess biological consequences in humans, effects on lymphocyte counts in 346 
patients with MS treated with DMF/MEF were retrospectively analyzed. 347 
DMF/MEF treatment led to a fast and profound reduction (44%) of ALC within the 348 
first year of treatment (figure 3 and table 2). ALCs remained suppressed beyond 349 
12 months until the end of the observation (24 months). Using a multivariate 350 
linear regression analysis DMF/MEF dose (coef. -1.05, 95%CI -2.09 - -0.01, 351 
p=0.047), age at treatment start (coef. -13.32, 95%CI -23.61 - -3.04, p=0.01), 352 
time point of sampling (coef. -73.97, 95%CI -133.68 - -14.26, p=0.02) and 353 
baseline ALC (coef. 0.51, 95%CI 0.33 – 0.70, p<0.001) influenced ALC, whereas 354 
previous use of immunosuppressive treatments and sex did not.  355 
Grade 2 or 3 lymphopenia was not present at baseline but occurred in 356 
27.8% (grade 2) and 5.6% (grade 3) of patients at the second year of DMF/MEF 357 





In 17 of 21 patients with available lymphocyte subpopulation data, the 359 
CD4+:CD8+ ratio correlated with ALC (Spearman rho correlation -0.52; p = 0.02; 360 
n = 21) and increased 1.5-fold in the first year and 2.3-fold in the second year 361 
(figure 4 and table 3). The increase in the CD4+:CD8+ ratio was driven by a 3.5-362 
fold higher suppression of CD8+ compared with CD4+ T cells (maximum 363 
reduction of CD4+ T cells 19% vs CD8+ T cells 66%). Finally, we analyzed 364 
lymphocyte data longitudinally from patients who switched from DMF/MEF to 365 
DMF. In general, the LI normalized for dosage of the DMF component increased 366 
in 6 of 7 patients, with an increase of median (IQR) LI from -4.33 (4.83) to -1.04 367 
(4.33) (Mann–Whitney U test, p = 0.04) after switching from DMF/MEF to DMF. 368 
In addition, when analyzing the ALC values without normalization to DMF 369 
dosage, an ALC increase in 4 of 7 patients was observed despite an increase of 370 
DMF dosage of 23%. One patient demonstrated stable ALCs, with a 100% 371 
increase in DMF dose. In the remaining 2 patients, both experienced a further 372 
decrease of ALCs, with a 78% increased DMF dose after withdrawal of MEF. 373 
 374 
Discussion 375 
Fumaderm® provided initial evidence of the potential therapeutic effects of 376 
fumarates in patients with MS.17, 18 The specific in vivo pharmacokinetic, 377 
pharmacodynamic, and immunologic effects of DMF and MEF salts in 378 
Fumaderm® have not been investigated.7 In vitro studies have demonstrated 379 
differential effects of DMF and MEF, which may provide insight to the in vivo 380 





observed for a targeted set of biological properties, including Kelch-like ECH-382 
associated protein 1 (Keap1) modification, Nrf2 activation, and GSH consumption 383 
and biosynthesis.7 DMF and MMF could potentially inhibit the activation of 384 
lymphoid and myeloid cells by downregulation of aerobic glycolysis via the 385 
succination and inactivation of glyceraldehyde 3-phosphate dehydrogenase 386 
(GAPDH).19 In addition, DMF and MMF activate endogenous detoxifying and 387 
antioxidant pathway genes through binding to Keap1, activating Nrf2 388 
transcriptional activity, and modulating GSH levels and activating GSH 389 
biosynthesis.7, 20  390 
A primary goal of these studies was to determine whether 391 
coadministration of DMF and MEF would provide an additive response or trigger 392 
unique biological responses in vivo. An unbiased transcriptional approach was 393 
used to characterize the differences between DMF, MEF, and DMF/MEF under 394 
steady-state exposure in vivo. The individual contributions of DMF and MEF were 395 
explored using doses that reflected the composition of Fumaderm®. Oral 396 
administration of DMF and MEF showed significant differences in their 397 
biodistribution and excretion profiles in mice, rats, and monkeys. MEF exhibited 398 
10- to 20-fold higher compound exposure in the kidney relative to MMF. 399 
Compared with systemic exposure, DMF levels were 4-fold higher than MEF 400 
levels in the brain. This could indicate that DMF might be more potent in directly 401 
targeting oxidative stress pathways in the CNS.  402 
In mice, DMF showed preferential modulation of transcripts in tissues 403 





showed a preference for transcript modulation in the kidney and MLN. This 405 
difference with MEF might be explained by its remarkably reduced concentration 406 
and area under the curve compared with DMF, which are likely the result of the 407 
combination of a lower relative dose and increased renal excretion. However, 408 
these effects might also be associated with individual transcriptional effects of the 409 
2 compounds, as the number of DEGs modulated by DMF are considerably 410 
higher in organs with exposure similar to MEF, such as the kidney. It remains 411 
uncertain whether the DMF-induced transcriptional changes are mediated by 412 
MMF signaling through HCAR221 (expressed on myeloid cells), through Nrf2 413 
(ubiquitously expressed in the body), or an additional pathway yet to be 414 
described. DMF likely has multiple therapeutic targets as it functions through 415 
both Nrf-2 dependent and independent pathways, indirect and/or direct inhibition 416 
of NF- κB, and modulation of oxidative stress-sensitive transcription factors and 417 
STATs through DMF-induced glutathione depletion and reactive oxygen species 418 
induction. 18, 22, 23 These analyses did not identify differential effects of DMF/MEF 419 
on Keap1 and GAPDH transcripts. In contrast, previous studies have shown 420 
post-transcriptional regulation through direct modification of activity of proteins 421 
such as Keap1 and GAPDH.19, 24 Specifically, DMF modification of lipid metabolic 422 
pathways and impairment of aerobic glycolysis and GAPDH activity by direct 423 
modification of the GAPDH protein itself are both related to DMF-induced 424 
immunological changes.19, 24 There are legitimate questions about whether the 425 
GAPDH preclinical data at high doses is relevant for human subjects that have 426 





be active in vivo. Pharmacodynamic data of DMF and MEF monotherapies 428 
andcombined DMF/MEF treatment, as well as DEG data assessing compounds’ 429 
interactions, indicate that differential gene expression may be more complex than 430 
increasing potency or total dosage. It is not known whether the fumarate tissue 431 
distribution and gene-expression profiles shown in animals in this analysis differ 432 
from that in humans.    433 
Our analyses of lymphocyte kinetics in patients with MS support the 434 
pharmacodynamic results. In patients who switched from DMF/MEF to DMF 435 
monotherapy, ALC increased even after normalization for DMF dosage. A 436 
pronounced and early reduction of ALCs during treatment with DMF/MEF was 437 
shown over a follow up of 24 months. Treatment of patients with MS with 438 
DMF/MEF led to an increase in the CD4+:CD8+ ratio, with a predominant 439 
reduction of CD8+ cells. Similar increases in CD4+:CD8+ ratios were observed in 440 
DMF/MEF-treated patients with psoriasis,9 yet this appears to be more 441 
pronounced than in patients with MS receiving DMF monotherapy (1.4-fold).25 In 442 
a recent study, DMF monotherapy shifted the immunophenotype of circulating 443 
lymphocyte subsets, and ALC closely correlated with CD4+ and CD8+ T-cell 444 
counts.26 No increased risk of serious infection was observed in patients with low 445 
T-cell subset counts.26  446 
Owing to the limited sample size, data analyses were limited, especially 447 
for T-cell subpopulations. Despite these limitations, multivariate regression 448 
analysis demonstrated that ALC was significantly forecasted by age, baseline 449 





are also known parameters predicting baseline ALC during DMF monotherapy, 451 
further supporting our analysis.27 Specifically,  previous analyses found that age 452 
≥60 years and a baseline ALC <2 g/L are independent risk factors for the 453 
development of a severe lymphopenia during DMF therapy.27 The small 454 
subpopulation of patients from our study that switched from DMF/MEF to DMF 455 
and exhibited an increase in ALC had a mean (SD) age of 54.1 (14.9) years.28, 29 456 
The retrospective design with intervals between testing not being well defined 457 
might introduce bias in the results. 458 
In conclusion, our experimental and clinical data provide evidence for 459 
different immunological effector mechanisms of DMF compared with MEF. It is 460 
not clear whether these different pathways are associated with lymphopenia 461 
induced by FAEs, yet this study provides data on potential mechanisms for the 462 
individual therapies. Although several mechanisms leading to lymphopenia have 463 
been proposed (e.g., apoptosis, GSH depletion, oxidative stress, bone marrow 464 
affection), exact pathomechanisms remain elusive.6, 7, 20, 30 Prolonged severe and 465 
moderate lymphopenia is considered a risk factor for very rare cases of 466 
progressive multifocal leukoencephalopathy in patients treated with DMF; 467 
therefore, identifying the differential effects of FAEs on lymphocyte counts is 468 





Total 5 figures and Tables 470 
Table 1. Distribution of lymphopenia grade 1–4 in DMF/MEF-treated patients 471 
Lymphopenia, n/N (%) 
Before 
DMF/MEF 
1st year of 
DMF/MEF 
2nd year of 
DMF/MEF 
No. of patients 
with lymphopenia 
(1st and 2nd year) 
No lymphopenia, 
>900/µl 
27/28 (96.4) 24/31 (77.4) 8/18 (44.4) 21/32 (65.6) 
Grade 1, 800–900/µl 1/28 (3.6) 4/31 (12.9) 4/18 (22.2) 4/32 (12.5) 
Grade 2, 500–799/µl 0/28(0) 1/31 (3.2) 5/18 (27.8) 5/32 (15.6) 
Grade 3, 200–500/µl 0/28 (0) 2/31 (6.5) 1/18 (5.6) 2/32 (6.3) 
Abbreviations: DMF = dimethyl fumarate; MEF = monoethyl fumarate. 472 





Table 2. White blood cell data from DMF/MEF-treated patients 474 
Month Mean (SEM) N 
0 1.80 (0.11) 28 
3 1.49 (0.12) 18 
6 1.00 (0.12) 12 
9 1.14 (0.11) 14 
12 1.01 (0.17) 13 
15 1.10 (0.26) 10 
18 1.01 (0.15) 10 
21 0.98 (0.12) 4 
24 1.00 (0.19) 6 
 475 
The table shows absolute lymphocyte counts in DMF/MEF-treated patients. 476 
Mean (SEM) lymphocyte counts (× 109/L) over 3-month periods for patients 477 
treated with DMF/MEF. ALC = absolute lymphocyte count; DMF = dimethyl 478 
fumarate; MEF = monoethyl fumarate. 479 





Table 3. CD4+:CD8+ ratio correlated with lymphocyte count 481 
DMF/MEF 









Before DMF/MEF (n=5) 468 (434)  301 (194)  1.56 
1st year of treatment 
(n=6) 374 (203) -20% 161 (219) -47% 2.32 
2nd year of treatment 
(n=10) 378 (399) -19% 103 (199) -66% 3.69 
 482 
The median and percentage change for CD4+ and CD8+ T cells are shown below 483 
the figure. DMF = dimethyl fumarate; IQR = interquartile range; MEF = monoethyl 484 
fumarate. 485 





Figure 1 Tissue distribution of MEF and DMF metabolite (MMF) in mice and rats  487 
 488 
Figure 1 legend (A–D) Mice and rats were administered a single dose of DMF 489 
(100 mg/kg) (A and C) or MEF (79 mg/kg) (B and D). Plasma and tissues levels 490 





minutes after dosing. Percentages above each bar represent the percent tissue 492 
penetration relative to plasma concentration. (E) Plasma to brain ratios for DMF 493 
and MEF treatment in mice and rats highlight significantly higher DMF (MMF) 494 
brain exposure (p < 0.001 for both species). (F) Plasma to kidney ratios for DMF 495 
and MEF treatment in mice and rats indicate significantly lower kidney exposure 496 
for DMF treatment compared with MEF ( **p < 0.01 and ****p < 0.001 in mice and 497 
rats, respectively). DMF = dimethyl fumarate; MEF = monoethyl fumarate; MMF = 498 






Figure 2 (A) DMF and MEF specificity across tissues and blood and (B) 501 
magnitude of interaction effect in mice 502 
 503 
Figure 2 legend (A) After pooling all tissues, the absolute value in each tissue of 504 
the group averages (DMF – vehicle) and (MEF – vehicle) were subjected to 505 
unsupervised hierarchical clustering (n = 7 biological sample sets each) for the 506 
487 DMF-specific and 224 MEF-specific probe sets. The relative magnitude of 507 





pronounced in MLN, ILN, spleen, and whole blood, whereas MEF specificity is 509 
most evident in the kidney and MLN. (B) For each of the 132 interaction probe 510 
sets, the absolute value of the difference of (DMF – vehicle) and (combination – 511 
MEF) was subjected to unsupervised hierarchical clustering. The interaction 512 
effect in each tissue is shown. An interaction between DMF and MEF is most 513 
pronounced in the immunological tissues: whole blood, MLN, ILN, and spleen. 514 
DMF = dimethyl fumarate; ILN = inguinal lymph node; MEF = monoethyl 515 









Figure 3 legend The figure shows absolute lymphocyte counts f in DMF/MEF-521 
treated patients. Mean (SEM) lymphocyte counts (× 109/L) over 3-month periods 522 
for patients treated with DMF/MEF. ALC = absolute lymphocyte count; DMF = 523 





Figure 4 CD4+:CD8+ ratio correlated with lymphocyte count  525 
 526 
Figure 4 legend CD4+ and CD8+ T cells in patients before DMF/MEF and 1 and 527 
2 years after DMF/MEF treatment. The box and whiskers plot shows median, 528 
IQR, and minimum/maximum for the CD4+:CD8+ ratio. DMF = dimethyl fumarate; 529 
IQR = interquartile range; MEF = monoethyl fumarate. 530 





Supplementary tables and figures = limited to 3 figures / tables  532 
Table e-1 Characteristics of DMF/MEF-treated patients with MS 533 
Characteristic Patients (N = 36) 
MS disease course, n/N  
RRMS or relapsing progressive MS 18/36 
Progressive MS 17/36 
Neuromyelitis optica 1/36 
Any previous MS medication, n/N 28/36 
MS therapy within 3 months before switch, n/N  
None 26/36 




Mean (SD) age at switch to MEF/DMF, y 56 (10.6) 
Female, n/N 24/36 
MS duration (SD) at switch to MEF/DMF, y 13.1 (7.8) 
IV steroids at baseline (within 2 weeks), n/N 3/36 
Mean (SD) IV steroids dose, mg 1167 (577) 
Immunosuppressive drug in medical history, n/N 16/36 
Mitoxantrone, n/N 14/36 
Mean (SD) cumulative dose of mitoxantrone, 






Mean (SD) interval between mitoxantrone and 
Fumaderm©, y 
2.4 (1.9) 
Azathioprine, n/N 3/36 
Mean (SD) interval between azathioprine and 
Fumaderm©, y 
7.7 (6.8) 
Methotrexate, n/N 2/36 
Mean (SD) interval between methotrexate and 
Fumaderm©, y 
2 (1.4) 
Switch MEF/DMF to DMF  
Mean (SD) therapy durations MEF/DMF, mo 12 (8) 
Mean (SD) follow-up during DMF, mo 7.7 (4.1) 
No therapy-free interval, n/N 6/7 
Therapy-free interval, wk (n) 6 (1) 
Abbreviations: DMF = dimethyl fumarate; MEF = monoethyl fumarate; MS = 534 






(NEW) Table e-2 Specific genes/pathways in mice most impacted by DMF and MEF 537 
Pathways Gene Symbols -log (P-value) 
Interaction Pathways   
Aldosterone Signaling in Epithelial Cells DNAJA1, DNAJB1, HSPA8, HSPH1, SOS1 3.13E+00 
Assembly of RNA Polymerase III Complex GTF3C4, GTF3C2 2.79E+00 
Unfolded protein response Hspa1b, HSPA8, HSPH1 2.68E+00 
Huntington's Disease Signaling Hspa1b, DNAJB1, HSPA8, NCOR1, SOS1 2.34E+00 
DMF-specific Pathways   
NRF2-mediated Oxidative Stress 
Response 
SQSTM1, GSTA3, GSTA5, GCLC, CBR1, TXN, NQO1, GSTK1, MGST1, 
PRDX1, GSTM1, GSTM5, CAT, AOX1, MAFG, FTL, GSTP1, FTH1 9.27E+00 
Xenobiotic Metabolism Signaling 
GSTA3, GSTA5, GCLC, UGT2B7, UGT1A9 (includes others), CAMK2D, 
Ces1g, NQO1, GSTK1, MGST1, ESD, GSTM1, GSTM5, CAT, 
UGT2B28, FTL, NDST1, GSTP1, ABCC3, UGT1A6 
7.92E+00 
Glutathione-mediated Detoxification GSTA3, GSTA5, GSTM1, GSTM5, GSTP1, GSTK1, MGST1 6.48E+00 
Aryl Hydrocarbon Receptor Signaling GSTA3, GSTA5, GSTM1, GSTM5, RBL1, NQO1, GSTP1, GSTK1, CTSD, MGST1 4.13E+00 
Nicotine Degradation III UGT2B7, UGT1A9 (includes others), AOX1, UGT2B28, Aox3, UGT1A6 3.71E+00 
Formaldehyde Oxidation II (Glutathione-
dependent) ADH5, ESD 3.61E+00 
Nicotine Degradation II UGT2B7, UGT1A9 (includes others), AOX1, UGT2B28, Aox3, UGT1A6 3.34E+00 
Serotonin Degradation UGT2B7, UGT1A9 (includes others), ADH5, ALDH2, UGT2B28, UGT1A6 3.30E+00 
LPS/IL-1 Mediated Inhibition of RXR 
Function 
GSTA3, GSTA5, GSTM1, GSTM5, CAT, APOE, NDST1, GSTP1, 
GSTK1, MGST1, ABCC3 3.14E+00 
Thyroid Hormone Metabolism II (via 
Conjugation and/or Degradation) UGT2B7, UGT1A9 (includes others), UGT2B28, UGT1A6 2.67E+00 
Pentose Phosphate Pathway (Oxidative 





Pathways Gene Symbols -log (P-value) 
Glutathione Redox Reactions I PRDX6, GSTK1, MGST1 2.51E+00 
Superoxide Radicals Degradation CAT, NQO1 2.31E+00 
Estrogen-mediated S-phase Entry E2F6, SKP2, RBL1 2.22E+00 
Role of BRCA1 in DNA Damage Response E2F6, RFC1, FAM175A, SMARCA2, RBL1 2.12E+00 
MEF-specific Pathways   
RhoA Signaling MYL12B, PIP5K1A, ROCK1, CDC42EP3, ACTR3, RDX 3.10E+00 
Apoptosis Signaling MAP2K7, KRAS, PARP1, ROCK1, CYCS 2.92E+00 
Signaling by Rho Family GTPases MAP2K7, GNG5, MYL12B, PIP5K1A, ROCK1, CDC42EP3, ACTR3, RDX 
2.91E+00 
Death Receptor Signaling MAP2K7, PARP1, TNKS2, ROCK1, CYCS 2.86E+00 
Sphingosine and Sphingosine-1-phosphate 
Metabolism SGPP1, ASAH1 
2.67E+00 
fMLP Signaling in Neutrophils KRAS, Calm1 (includes others), GNG5, PPP3CB, ACTR3 2.55E+00 
Cardiac Hypertrophy Signaling MAP2K7, KRAS, Calm1 (includes others), GNG5, MYL12B, PPP3CB, ROCK1 
2.41E+00 
autophagy NBR1, LAMP2, BECN1 2.40E+00 
RhoGDI Signaling GNG5, MYL12B, PIP5K1A, ROCK1, ACTR3, RDX 2.34E+00 
Ephrin Receptor Signaling KRAS, GNG5, RAP1B, ABI1, ROCK1, ACTR3 2.32E+00 
B Cell Receptor Signaling MAP2K7, KRAS, BCL6, Calm1 (includes others), RAP1B, PPP3CB 2.30E+00 
Role of NFAT in Cardiac Hypertrophy MAP2K7, CSNK1A1, KRAS, Calm1 (includes others), GNG5, PPP3CB 2.27E+00 
Regulation of IL-2 Expression in Activated 
and Anergic T Lymphocytes MAP2K7, KRAS, Calm1 (includes others), PPP3CB 
2.26E+00 
Axonal Guidance Signaling KRAS, GNG5, TUBB6, MYL12B, NRP1, RAP1B, PPP3CB, ROCK1, BRCC3, ACTR3 
2.25E+00 
Regulation of the Epithelial-Mesenchymal 
Transition Pathway MAP2K7, ESRP2, KRAS, PSEN2, FRS2, ZEB2 
2.21E+00 





Pathways Gene Symbols -log (P-value) 
UVA-Induced MAPK Signaling KRAS, PARP1, TNKS2, CYCS 2.10E+00 
Granzyme B Signaling PARP1, CYCS 2.06E+00 
Regulation of Actin-based Motility by Rho MYL12B, PIP5K1A, ROCK1, ACTR3 2.05E+00 
RAN Signaling RAN, KPNB1 2.01E+00 
Abbreviations: DMF = dimethyl fumarate; MEF = monoethyl fumarate; MS = multiple sclerosis; RRMS = relapsing-538 
remitting multiple sclerosis. 539 
 540 
 541 





(NEW) Table e-3 Specific pathways in mice most impacted by a combination of DMF and MEF 543 







Blood Aryl Hydrocarbon Receptor Signaling 1.17E-02 NQO1,TGM2 1.10E-03 
Blood Superoxide Radicals Degradation 1.25E-01 NQO1 2.19E-03 
Blood Pregnenolone Biosynthesis 7.69E-02 MICAL3 2.19E-03 
Blood Histidine Degradation VI 5.00E-02 MICAL3 3.31E-03 
Blood Ubiquinol-10 Biosynthesis (Eukaryotic) 3.33E-02 MICAL3 4.79E-03 
Brain Superoxide Radicals Degradation 1.25E-01 NQO1 6.31E-04 
Brain Nicotine Degradation III 1.37E-02 Aox3 5.37E-03 
Brain Nicotine Degradation II 1.18E-02 Aox3 6.31E-03 
Brain Hypoxia Signaling in the Cardiovascular System 1.47E-02 NQO1 6.92E-03 
ILN Aryl Hydrocarbon Receptor Signaling 1.17E-02 GSTM5,NQO1 7.76E-04 
ILN NRF2-mediated Oxidative Stress Response 1.03E-02 GSTM5,NQO1 1.29E-03 
ILN Superoxide Radicals Degradation 1.25E-01 NQO1 1.86E-03 
ILN Xenobiotic Metabolism Signaling 6.94E-03 GSTM5,NQO1 2.88E-03 
ILN Glutathione-mediated Detoxification 2.27E-02 GSTM5 8.71E-03 









Jejunum Glutathione-mediated Detoxification 1.82E-01 GSTA3,Gsta4,GSTA5,GSTK1,GSTM1,Gstm3,GSTM4,GSTM5 2.00E-15 










Jejunum Aryl Hydrocarbon Receptor Signaling 5.26E-02 ALDH1A1,GSTA3,GSTA5,GSTK1,GSTM1,Gstm3,GSTM4,GSTM5,NQO1 5.01E-11 
Jejunum PXR/RXR Activation 5.43E-02 ABCC2,ABCC3,ALDH1A1,Aldh1a7,GSTM1 6.17E-07 
Jejunum Serotonin Degradation 5.13E-02 ALDH1A1,Aldh1a7,UGT2B15,UGT2B7 1.51E-05 
Jejunum Glutathione Biosynthesis 1.82E-01 GCLC,GSS 1.78E-05 
Jejunum Histamine Degradation 6.90E-02 ALDH1A1,Aldh1a7 4.47E-04 
Jejunum Î³-glutamyl Cycle 7.14E-02 GCLC,GSS 6.03E-04 
Jejunum Fatty Acid Î±-oxidation 8.70E-02 ALDH1A1,Aldh1a7 6.92E-04 
Jejunum Oxidative Ethanol Degradation III 5.00E-02 ALDH1A1,Aldh1a7 6.92E-04 
Jejunum Putrescine Degradation III 6.67E-02 ALDH1A1,Aldh1a7 7.76E-04 
Jejunum Tryptophan Degradation X (Mammalian, via Tryptamine) 6.90E-02 ALDH1A1,Aldh1a7 8.71E-04 
Jejunum Ethanol Degradation IV 6.90E-02 ALDH1A1,Aldh1a7 8.71E-04 





Jejunum Sorbitol Degradation I 2.00E-01 SORD 2.45E-03 
Jejunum Retinoate Biosynthesis I 5.41E-02 AKR1B10,ALDH1A1 2.82E-03 
Jejunum Thyroid Hormone Metabolism II (via Conjugation and/or Degradation) 3.77E-02 UGT2B15,UGT2B7 2.82E-03 
Jejunum Ethanol Degradation II 4.65E-02 ALDH1A1,Aldh1a7 2.95E-03 
Jejunum Retinol Biosynthesis 4.44E-02 CES1,Ces1e 3.31E-03 
Jejunum Noradrenaline and Adrenaline Degradation 3.77E-02 ALDH1A1,Aldh1a7 3.55E-03 
Jejunum Nicotine Degradation III 2.74E-02 UGT2B15,UGT2B7 7.24E-03 
Jejunum L-serine Degradation 1.67E-01 SRR 7.41E-03 
Jejunum Melatonin Degradation I 3.03E-02 UGT2B15,UGT2B7 8.13E-03 
Jejunum Superpathway of Melatonin Degradation 2.47E-02 UGT2B15,UGT2B7 9.55E-03 
Jejunum Heme Degradation 9.09E-02 BLVRB 9.77E-03 
Jejunum Nicotine Degradation II 2.35E-02 UGT2B15,UGT2B7 9.77E-03 
Kidney LXR/RXR Activation 6.47E-02 ALB,APOA1,APOC1,APOC2,APOC3,APOE,GC,SERPINA1,TTR 7.41E-08 





Kidney NRF2-mediated Oxidative Stress Response 5.13E-02 
AOX1,EPHX1,GSR,GSTA3,Gstm3,GST
M4,GSTM5,GSTP1,HMOX1,NQO1 2.14E-07 
Kidney Glutathione-mediated Detoxification 1.14E-01 GSTA3,Gstm3,GSTM4,GSTM5,GSTP1 8.13E-07 










Kidney Nicotine Degradation III 6.85E-02 AOX1,CYP2D6,CYP2J2,UGT2B10,UGT2B15 1.91E-05 
Kidney IL-12 Signaling and Production in Macrophages 4.46E-02 
ALB,APOA1,APOC1,APOC2,APOC3,A
POE,SERPINA1 2.29E-05 
Kidney Clathrin-mediated Endocytosis Signaling 4.04E-02 
ALB,APOA1,APOC1,APOC2,APOC3,A
POE,ITGB6,SERPINA1 2.29E-05 
Kidney Aryl Hydrocarbon Receptor Signaling 4.09E-02 ALDH3A1,GSTA3,Gstm3,GSTM4,GSTM5,GSTP1,NQO1 3.02E-05 
Kidney Pentose Phosphate Pathway 1.30E-01 G6PD,PGD,TKT 3.89E-05 
Kidney Nicotine Degradation II 5.88E-02 AOX1,CYP2D6,CYP2J2,UGT2B10,UGT2B15 4.17E-05 
Kidney Production of Nitric Oxide and Reactive Oxygen Species in Macrophages 3.30E-02 
ALB,APOA1,APOC1,APOC2,APOC3,A
POE,SERPINA1 1.41E-04 
Kidney Heme Degradation 1.82E-01 BLVRB,HMOX1 2.34E-04 
Kidney Pentose Phosphate Pathway (Oxidative Branch) 1.82E-01 G6PD,PGD 3.89E-04 
Kidney Melatonin Degradation I 6.06E-02 CYP2D6,CYP2J2,UGT2B10,UGT2B15 3.98E-04 
Kidney Superpathway of Melatonin Degradation 4.94E-02 CYP2D6,CYP2J2,UGT2B10,UGT2B15 5.62E-04 
Kidney Coagulation System 7.89E-02 PLAU,PLAUR,SERPINA1 1.38E-03 
Kidney FXR/RXR Activation 3.64E-02 APOA1,APOC2,APOC3,APOE 2.14E-03 
Kidney Acute Phase Response Signaling 2.76E-02 ALB,APOA1,HMOX1,SERPINA1,TTR 4.37E-03 





MLN Airway Pathology in Chronic Obstructive Pulmonary Disease 1.82E-01 MMP2,MMP9 1.00E-04 
MLN NRF2-mediated Oxidative Stress Response 2.05E-02 GSTA3,GSTM5,HMOX1,NQO1 3.89E-04 
MLN Glutathione-mediated Detoxification 4.55E-02 GSTA3,GSTM5 1.32E-03 
MLN Xenobiotic Metabolism Signaling 1.39E-02 GSTA3,GSTM5,HMOX1,NQO1 1.78E-03 
MLN Hepatic Fibrosis / Hepatic Stellate Cell Activation 1.94E-02 AGTR1,MMP2,MMP9 2.40E-03 
MLN Aryl Hydrocarbon Receptor Signaling 1.75E-02 GSTA3,GSTM5,NQO1 2.45E-03 
MLN Inhibition of Matrix Metalloproteases 5.00E-02 MMP2,MMP9 2.57E-03 
MLN IL-8 Signaling 1.33E-02 HMOX1,MMP2,MMP9 5.62E-03 
MLN Glioma Invasiveness Signaling 3.03E-02 MMP2,MMP9 5.62E-03 
MLN Eicosanoid Signaling 2.33E-02 LTC4S,PTGDS 6.61E-03 
MLN Heme Degradation 9.09E-02 HMOX1 7.76E-03 
MLN LPS/IL-1 Mediated Inhibition of RXR Function 1.22E-02 GSTA3,GSTM5,HMGCS2 8.71E-03 
Spleen NRF2-mediated Oxidative Stress Response 1.54E-02 AOX1,GSTA3,GSTM5 8.13E-06 
Spleen Glutathione-mediated Detoxification 4.55E-02 GSTA3,GSTM5 2.04E-05 
Spleen Aryl Hydrocarbon Receptor Signaling 1.17E-02 GSTA3,GSTM5 5.25E-04 
Spleen LPS/IL-1 Mediated Inhibition of RXR Function 8.16E-03 GSTA3,GSTM5 1.29E-03 
Spleen Xenobiotic Metabolism Signaling 6.94E-03 GSTA3,GSTM5 1.95E-03 





Spleen Urate Biosynthesis/Inosine 5'-phosphate Degradation 4.35E-02 AOX1 3.63E-03 
Spleen Adenosine Nucleotides Degradation II 3.57E-02 AOX1 4.47E-03 
Spleen Purine Nucleotides Degradation II (Aerobic) 2.70E-02 AOX1 5.25E-03 
Abbreviations: DEG = differentially expressed gene; ILN = inguinal lymph node; MLN = mesenteric lymph node. 544 
Pathways with significant changes (p<0.01) after treatment of mice with the combination of DMF and MEF. 545 





Figure e-1 Steady-state tissue-specific DEGs in response to chronic DMF, MEF, 547 
and DMF/MEF administration in mice 548 
 549 
Tissue was harvested after 10 days of daily treatment with DMF, MEF, or 550 
DMF/MEF. DEGs were identified by comparing the groups DMF-vs-vehicle, 551 
MEF-vs-vehicle, and DMF/MEF-vs-vehicle in each tissue. The number in 552 
parentheses designates the total number of DEGs for that treatment. DEG = 553 
differentially expressed gene; DMF = dimethyl fumarate; ILN = inguinal lymph 554 
node; MLN = mesenteric lymph node; MEF = monoethyl fumarate. 555 
 556 
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